BRIEF published on 05/21/2025 at 23:05, 1 year 5 months ago Medicure Announces Q1 2025 Financial Results and Director Election Outcomes Net Loss Director Election Medicure Financial Results AGGRASTAT Sales Decline Pharmacy Revenue
PRESS RELEASE published on 05/21/2025 at 23:00, 1 year 5 months ago Medicure Reports Financial Results for Quarter Ended March 31, 2025 and Annual General Meeting Director Election Results Medicure Inc. reports Q1 2025 results with $5.5M net revenue, elects directors, and details financial performance. AGGRASTAT and ZYPITAMAG sales analyzed Medicure Inc. Net Revenue AGGRASTAT ZYPITAMAG Q1 2025 Results
BRIEF published on 04/25/2025 at 23:06, 1 year 5 months ago Medicure Inc. dévoile ses résultats financiers pour 2024 Medicure Inc. 2024 Marley Drug Financials Ventes D'AGGRASTAT® Chiffre D'affaires De ZYPITAMAG® Baisse De L'EBITDA Ajusté
BRIEF published on 04/25/2025 at 23:06, 1 year 5 months ago Medicure Inc. Reveals Financial Results for 2024 Medicure Inc. 2024 AGGRASTAT® Sales ZYPITAMAG® Revenue Marley Drug Financials Adjusted EBITDA Decline
PRESS RELEASE published on 04/25/2025 at 23:01, 1 year 5 months ago Medicure Reports Financial Results for Quarter and Year Ended December 31, 2024 Medicure Inc. reports total net revenue of $21.9 million for year ended Dec 31, 2024. AGGRASTAT & Marley Drug sales increase, while Adjusted EBITDA declines Adjusted EBITDA Medicure Inc. Marley Drug Net Revenue AGGRASTAT
BRIEF published on 04/23/2025 at 00:05, 1 year 6 months ago Medicure to Announce 2024 Financial Results Financial Results Conference Call Medicure AGGRASTAT® U.S. Pharmaceuticals
BRIEF published on 04/23/2025 at 00:05, 1 year 6 months ago Medicure annoncera ses résultats financiers pour 2024 Résultats Financiers Conférence Téléphonique Medicure AGGRASTAT® Produits Pharmaceutiques Américains
PRESS RELEASE published on 04/23/2025 at 00:00, 1 year 6 months ago Medicure to Present Financial Results on April 29, 2025 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2024 Medicure Inc. to present 2024 Year End Financial Results on April 29, 2025 via conference call. Focus on pharmaceuticals & healthcare products in US market Conference Call Pharmaceuticals Medicure Inc. Healthcare Products 2024 Year End Financial Results
BRIEF published on 04/11/2025 at 15:05, 1 year 6 months ago Medicure étend sa présence dans les pharmacies américaines avec l'acquisition de West Olympia Expansion Des Soins De Santé Medicure ZYPITAMAG® Acquisition De Pharmacies Olympia Ouest
BRIEF published on 04/11/2025 at 15:05, 1 year 6 months ago Medicure Expands U.S. Pharmacy Reach with West Olympia Acquisition Healthcare Expansion Medicure Pharmacy Acquisition West Olympia ZYPITAMAG®
Published on 10/23/2026 at 13:23, 2 hours 13 minutes ago Slam Mobilizes Drill Team to Moose Lake, Intersecting Broad Zones of Brecciated and Altered Rock With Visible Stibnite Along the Moose Lake Fault Zone
Published on 10/23/2026 at 13:00, 2 hours 36 minutes ago First Canadian Graphite Inc. Announces Flow-Through Financing
Published on 10/23/2026 at 13:00, 2 hours 36 minutes ago First Canadian Graphite Inc. annonce un financement accréditif
Published on 10/23/2026 at 02:20, 13 hours 16 minutes ago Apex Announces Nasdaq Listing and Pricing of US$1.86 Million Offering
Published on 10/22/2026 at 23:30, 16 hours 6 minutes ago Cypher Announces Subscription Receipt Offering
Published on 10/23/2026 at 15:24, 11 minutes ago Form 8.3 - The Vanguard Group, Inc.: RHI Magnesita N.V.
Published on 10/23/2026 at 15:24, 12 minutes ago Form 8.3 - The Vanguard Group, Inc.: Permanent TSB Group Holdings plc
Published on 10/23/2026 at 07:00, 8 hours 36 minutes ago Safran publie son chiffre d’affaires du 3e trimestre 2026
Published on 10/22/2026 at 18:00, 21 hours 36 minutes ago THERMADOR GROUPE : Completion of the share buy-back programme launched in August
Published on 10/22/2026 at 18:00, 21 hours 36 minutes ago THERMADOR GROUPE : Fin du programme de rachat d’actions débuté en août
Published on 10/22/2026 at 18:00, 21 hours 36 minutes ago bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics
